138 related articles for article (PubMed ID: 31778284)
1. The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells.
Duckett MM; Phung SK; Nguyen L; Khammanivong A; Dickerson E; Dusenbery K; Lawrence J
Vet Comp Oncol; 2020 Mar; 18(1):128-140. PubMed ID: 31778284
[TBL] [Abstract][Full Text] [Related]
2. Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells.
Mantovani FB; Morrison JA; Mutsaers AJ
BMC Vet Res; 2016 May; 12():82. PubMed ID: 27245053
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines.
Fitzpatrick CL; Farese JP; Milner RJ; Salute ME; Rajon DA; Morris CG; Bova FJ; Lurie DM; Siemann DW
Am J Vet Res; 2008 Sep; 69(9):1197-202. PubMed ID: 18764694
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs.
Royals SR; Farese JP; Milner RJ; Lee-Ambrose L; van Gilder J
Am J Vet Res; 2005 Nov; 66(11):1961-7. PubMed ID: 16334957
[TBL] [Abstract][Full Text] [Related]
5. Impact of radiation dose and pre-treatment pain levels on survival in dogs undergoing radiotherapy with or without chemotherapy for presumed extremity osteosarcoma.
Nolan MW; Green NA; DiVito EM; Lascelles BDX; Haney SM
Vet Comp Oncol; 2020 Dec; 18(4):538-547. PubMed ID: 32048435
[TBL] [Abstract][Full Text] [Related]
6. Treatment of canine osteosarcoma for limb preservation using osteotomy, adjuvant radiotherapy and chemotherapy (a case report).
Theilen GH; Leighton R; Pool R; Park RD
Vet Med Small Anim Clin; 1977 Feb; 72(2):179-83. PubMed ID: 265130
[No Abstract] [Full Text] [Related]
7. The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.
Alegre F; Ormonde AR; Godinez DR; Illendula A; Bushweller JH; Wittenburg LA
Vet Comp Oncol; 2020 Mar; 18(1):52-63. PubMed ID: 31381810
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
Inkol JM; Poon AC; Mutsaers AJ
Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
[TBL] [Abstract][Full Text] [Related]
9. Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.
Hosoya K; Murahari S; Laio A; London CA; Couto CG; Kisseberth WC
Am J Vet Res; 2008 Apr; 69(4):519-26. PubMed ID: 18380584
[TBL] [Abstract][Full Text] [Related]
10. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
York D; Withers SS; Watson KD; Seo KW; Rebhun RB
Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
[TBL] [Abstract][Full Text] [Related]
11. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer.
Judge SJ; Yanagisawa M; Sturgill IR; Bateni SB; Gingrich AA; Foltz JA; Lee DA; Modiano JF; Monjazeb AM; Culp WTN; Rebhun RB; Murphy WJ; Kent MS; Canter RJ
PLoS One; 2020; 15(2):e0224775. PubMed ID: 32084139
[TBL] [Abstract][Full Text] [Related]
12. Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines.
Ong SM; Saeki K; Tanaka Y; Nishimura R; Nakagawa T
Vet J; 2016 Dec; 218():51-59. PubMed ID: 27938709
[TBL] [Abstract][Full Text] [Related]
13. Treatment of canine appendicular osteosarcoma using cobalt 60 radiation and intraarterial cisplatin.
Heidner GL; Page RL; McEntee MC; Dodge RK; Thrall DE
J Vet Intern Med; 1991; 5(6):313-6. PubMed ID: 1779423
[TBL] [Abstract][Full Text] [Related]
14. Effect of timing of bisphosphonate administration on canine osteosarcoma cells undergoing radiation therapy.
Hoddinott K; Oblak ML; Wood GA; Boston S; Mutsaers AJ
Can J Vet Res; 2020 Jul; 84(3):225-229. PubMed ID: 32801458
[TBL] [Abstract][Full Text] [Related]
15. The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study.
Porcelli L; Garofoli M; Di Fonte R; Fucci L; Volpicella M; Strippoli S; Guida M; Azzariti A
Sci Rep; 2020 Jun; 10(1):10465. PubMed ID: 32591592
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiation therapy for canine multilobular osteochondrosarcoma: Eight cases.
Sweet KA; Nolan MW; Yoshikawa H; Gieger TL
Vet Comp Oncol; 2020 Mar; 18(1):76-83. PubMed ID: 30989784
[TBL] [Abstract][Full Text] [Related]
17. Melarsomine suppresses canine osteosarcoma cell survival via inhibition of Hedgehog-GLI signaling.
Nam A; Kim T; Li Q; Rebhun RB; Youn HY; Seo KW
J Vet Med Sci; 2019 Dec; 81(12):1722-1729. PubMed ID: 31645504
[TBL] [Abstract][Full Text] [Related]
18. The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro.
Farese JP; Ashton J; Milner R; Ambrose LL; Van Gilder J
In Vitro Cell Dev Biol Anim; 2004; 40(3-4):113-7. PubMed ID: 15311969
[TBL] [Abstract][Full Text] [Related]
19. Palliative radiation therapy for canine osteosarcoma.
Mayer MN; Grier CK
Can Vet J; 2006 Jul; 47(7):707-9. PubMed ID: 16898117
[No Abstract] [Full Text] [Related]
20. The effects of sulforaphane on canine osteosarcoma proliferation and invasion.
Rizzo VL; Levine CB; Wakshlag JJ
Vet Comp Oncol; 2017 Sep; 15(3):718-730. PubMed ID: 27045198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
